Given that MEKi elicit immunologic effects as well as direct antitumor effects (10, 46) and are actively being combined with immune checkpoint inhibitors in breast cancer, suppression of MDSC recruitment via transcriptional inhibition of CXCL1/2/8 may be a novel mechanism of combinatorial activity. This evidence concerns the gene CXCL1 and breast carcinoma.